Month: May 2022

Identity and Access Management Cyber-Security Provider BIO-key’s Q1 Revenue Improved to $1.9M, Driven by 205% Increase in Software License Fees; Investor Call Today at 10am ET

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

WALL, N.J., May 16, 2022 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) and large-scale identity solutions, today reported results for its first quarter ended March 31, 2022 (Q1’22). BIO-key is hosting a conference call today at 10:00 a.m. ET (details below) to review its results and outlook. BIO-key’s revenue improved 3% to $1.94M in Q1’22 from $1.89M in Q1’21 and 108% from $935K in Q4 2021 driven by a $981,000 increase in software license fees year over year. BIO-key is focused on growing its base of annual recurring software license fees which provide more predictable revenue trends and higher margins than its more episodic hardware revenues. Recent Highlights:Expanding...

GCM Mining Declares June 15, 2022 Monthly Dividend

Written by Customer Service on May 16, 2022. Posted in Dividend Reports And Estimates.

TORONTO, May 16, 2022 (GLOBE NEWSWIRE) — GCM Mining Corp. (“GCM Mining” or the “Company”) (TSX: GCM, OTCQX: TPRFF) announced today that its Board of Directors has declared the next monthly dividend of CA$0.015 per common share will be paid on June 15, 2022 to shareholders of record as of the close of business on May 31, 2022. About GCM Mining Corp. GCM Mining is a mid-tier gold producer with a proven track record of mine building and operating in Latin America. In Colombia, the Company is a leading high-grade underground gold and silver producer with several mines in operation at its Segovia Operations. Segovia produced 206,389 ounces of gold in 2021. In Guyana, the Company is advancing its fully funded Toroparu Project, one of the largest undeveloped gold/copper projects in the Americas, which is expected to commence production...

FTI Consulting Strengthens Health Solutions Practice with Addition of Anne Winter

Written by Customer Service on May 16, 2022. Posted in Public Companies.

WASHINGTON, May 16, 2022 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Anne Winter as a Senior Managing Director within the Company’s Health Solutions practice, where she will focus on Medicaid managed care and the pharmaceutical industry. Ms. Winter, who is based in Scottsdale, Ariz., has more than 25 years of experience in Medicaid policy and regulation, managed care, operational improvement, new market entry strategy, situational analyses, procurement, operational readiness reviews, capabilities assessments and pharmaceutical supply chain. She joins FTI Consulting from Health Management Associates, where she consulted with clients on Medicaid market strategy. “Anne brings deep managed care operational knowledge to our growing practice,” said Charles Overstreet, Global Leader of the Health...

ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update

Written by Customer Service on May 16, 2022. Posted in Public Companies.

Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysis YONKERS, N.Y., May 16, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the first quarter ended March 31, 2022. “I am very pleased to announce that we have eclipsed the enrollment threshold, meaning over 60% of the methicillin-resistant Staph aureus (MRSA) patients, needed for the interim futility analysis of our Phase 3 DISRUPT study to be conducted and we currently have about two-thirds of the...

Revival Gold Delivers Impressive Resource Update at Beartrack-Arnett

Written by Customer Service on May 16, 2022. Posted in Public Companies.

Figure 1 Beartrack-Arnett Project AreaFigure 2 Joss Zone Block Model Isometric ViewTORONTO, May 16, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) is pleased to announce the results of an updated mineral resource estimate (“Mineral Resource”) on the Company’s Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Idaho, USA. HighlightsThe updated Mineral Resource was completed by Wood plc (“Wood”) based on drill results through the end of 2021 and contains:An Indicated Mineral Resource of 65.0 million tonnes at 1.01 g/t gold containing 2.11 million ounces of gold1, an increase of 56% over the 2020 Indicated Mineral Resource2; and, An Inferred Mineral Resource of 46.2 million tonnes at 1.31 g/t gold containing 1.94 million ounces of gold1, an increase...

Form 8.3 – [LXI REIT PLC – 13 05 2022] – CGWL

Written by Customer Service on May 16, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree LXI REIT PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, following positive clinical strategy meeting with FDA earlier this year Results from a 12-week interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned in June 2022; Phase 2b or Phase 3 clinical trial of MAU868 expected to initiate in 2023 Strong balance sheet with approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022 and access to a $45.0 million credit facility expected to fund operations to Q2 2024BRISBANE, Calif., May 16, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative...

Dynacor Reports a Quarterly Record Net Income of $5.1 Million in Q1-2022 (US$0.13 or CA$0.16 Per Share) and Sales of $50.1 Million

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

Sales in million US$ Sales in million US$ – 2021 and 2022MONTREAL, May 16, 2022 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG) (Dynacor or the Corporation) released its unaudited condensed interim consolidated financial statements and the management’s discussion and analysis (MD&A) for the first quarter ended March 31, 2022. These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation’s website www.dynacor.com. (All figures in this press release are in Ms of US$ unless stated otherwise. All amounts per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding). Q1-2022 OVERVIEW AND HIGHLIGHTS OVERVIEW Dynacor completed the three-month period ended March 31, 2022 (“Q1-2022”) with...

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

FDA assigns PDUFA action date of October 8, 2022 Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved Ended Q1 with cash, cash equivalents, restricted cash and investments of $65.6 million BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. Business UpdateAnnounced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for FUROSCIX, a proprietary formulation...

AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

Written by Customer Service on May 16, 2022. Posted in Earnings Releases And Operating Results.

– First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical potential with checkpoint inhibitors – On track to commence Phase 2 study for lead program of Ampligen for pancreatic cancer Q3 2022 – Focus on further advancement of oncology pipeline and well-positioned to achieve multiple clinical and regulatory value-driving milestones throughout 2022 – Cash position of $44.5 million expected to fund company through the end of 2023 OCALA, Fla., May 16, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused...

Month: May 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals